Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 6 days agoIt will be historic when it is no longer the first prescribed agent in HER2+ mBC and Enhertu may...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 3 days agoDr. Dennis Slamon, a world-renowned oncologist and scientist whose groundbreaking research has...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 5 days agoARX788 is attempting to enter a crowded field, Enhertu (trastuzumab deruxtecan) is the standard of...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 6 days ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 22 hours agoA New Top Biotech Stock Corcept Therapeutics is a newer addition to the list of leading biotech...
...Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer - ALX...
Benzinga· 6 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt,
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
Zacks via Yahoo Finance· 3 days agoThe outlook for 2024 is ordinary as well. Competition from biosimilars for established cancer...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 4 days agoIn 2024, Teva expects Uzedy sales of approximately $80 million. Teva markets biosimilar versions of...